HUTCHMED (China) (HMDCF) Current Assets (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Current Assets came in at $1.6 billion in Q2 2026, down 2.44% year-over-year from $1.6 billion in Q2 2025, and down 0.89% quarter-over-quarter from $1.6 billion in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Current Assets (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Current Assets for 12 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Current Assets fell 2.44% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $1.6 billion, a 2.44% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 2419.89% from the prior year.
- Current Assets was $1.6 billion for Q2 2026 at HUTCHMED (China), down from $1.6 billion in the prior quarter.
- Over five years, Current Assets peaked at $1.6 billion in Q2 2025 and troughed at -$73.9 million in Q4 2023.
- A 5-year average of $952.5 million and a median of $1.0 billion in 2024 frame the typical range for Current Assets.
- Across the five-year window, Current Assets plunged 108.8% in 2023 and jumped 2419.89% in 2025, its largest moves.
- Over 5 years, Current Assets stood at $839.9 million in 2022, then sank by 108.8% to -$73.9 million in 2023, then advanced by 8.63% to -$67.6 million in 2024, then jumped by 2419.89% to $1.6 billion in 2025, then declined by 0.89% to $1.6 billion in 2026.
- The last three Current Assets figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | 4.74 Bn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 1.55 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.55 Bn |
| Dec 31, 2025 | 1.57 Bn |
| Jun 30, 2025 | 1.59 Bn |
| Dec 31, 2024 | -67.56 Mn |
| Jun 30, 2024 | 1.05 Bn |
| Dec 31, 2023 | -73.94 Mn |
| Jun 30, 2023 | 1.09 Bn |
| Dec 31, 2022 | 839.89 Mn |
| Jun 30, 2022 | 1.02 Bn |
| Dec 31, 2021 | 1.21 Bn |
| Jun 30, 2021 | 1.09 Bn |
| Mar 31, 2021 | 496.23 Mn |
| Dec 31, 2020 | 530.74 Mn |
| Jun 30, 2020 | 374.73 Mn |
| Dec 31, 2019 | 317.02 Mn |
| Sep 30, 2019 | 277.08 Mn |
| Jun 30, 2019 | 309.50 Mn |
| Mar 31, 2019 | 349.99 Mn |
| Dec 31, 2018 | 370.54 Mn |
| Jun 30, 2018 | 394.68 Mn |